Award Number: DAMD17-01-1-0455

TITLE: DNA Vaccination to Overcome Peripheral Tolerance

AD

PRINCIPAL INVESTIGATOR: Wei-Zen Wei, Ph.D.

CONTRACTING ORGANIZATION: Wayne State University Detroit, Michigan 48202

REPORT DATE: August 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030313 118

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing this burden estimate or any ot the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any ot				isting data sources, gathering and maintaining
reducing this burden to Washington Headquarters	Services, Directorate for Information Operations a			
Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503 1. AGENCY USE ONLY (Leave blank) 2. REPORT DATE 3. REPORT TYPE AND DATES C			DATES COVERI	Ð
·····	August 2002	Annual (1 Aug		
4. TITLE AND SUBTITLE		_ _	5. FUNDING N	
DNA Vaccination to	Overcome Periphera.	l Tolerance	DAMD17-01	-1-0455
				,
6. AUTHOR(S)				-
Wei-Zen Wei, Ph.D.	•			
· · · · · ·				
7. PERFORMING ORGANIZATION N	AME(S) AND ADDRESS(ES)		8. PERFORMING ORGANIZATION REPORT NUMBER	
Wayne State Univers	itv	×		
-	48202			
,				
E-Mail: weiw@karmanos.org				
9. SPONSORING / MONITORING A	GENCY NAME(S) AND ADDRESS(ES		10 SPONSOR	NG / MONITORING
		1	AGENCY REPORT NUMBER	
U.S. Army Medical Research and				
Fort Detrick, Maryland 21702-50	012			
				· · · · · · · · · · · · · · · · · · ·
11. SUPPLEMENTARY NOTES				
	•			
12a. DISTRIBUTION / AVAILABILITY				12b. DISTRIBUTION CODE
Approved for Public Rel	lease; Distribution Unl	imited		
13. Abstract (Maximum 200 Words)	l (abstract should contain no proprie	tary or confidential info	rmation)	
The vaccination efficient	cacy of DNA encoding auto	logous rat ErbB-2	(neu) or hete	rologous human ErbB-2
(Her-2) is compared in rat n	eu transgenic mice (BALB	neuT). Cross react	tivity betwee	n Her-2 and rat neu was
tested initially by immunizing	ng normal mice, twice, i.m.	with pEFBosGM-0	CSF and pCN	AVE2TM or pCDneuTM.
E2TM and neuTM encodes	the extracellular (ECD) and	transmembrane (7	ΓM) domains	of Her-2 and neu,
respectively. Immunized m	ice were challenged with m	ammary tumor D2	F2 expressin	g Her-2 (D2F2/E2) or
neu (D2F2/neu). All mice i	mmunized with E2TM or ne	euTM rejected tum	ors expressi	ng the corresponding
antigen. There is significan	t cross-protection against tu	mors expressing th	ne non-corres	ponding ErbB-2, although
the antibodies demonstrated				
neuTM but not E2TM delay	red spontaneous tumorigene	sis. Therefore, He	er-2 and rat n	eu are cross-reactive
antigens in normal mice, bu	t only autologous neu, not h	eterologous Her-2	induced prot	tective immunity in NeuT
transgenic mice. This may	indicate a lack of cross-reac	tivity of antibodies	s which are c	ritical in inhibiting NeuT
tumor. To enhance the imm	unogenicity of autologous	ErbB-2, an adjuvar	nt sequence o	f Pan DR Reactive
Epitope (PADRE) has been	cloned into human ErbB-2	and the immunoge	nicity is bein	g tested.
14. SUBJECT TERMS			-	
vaccination, DNA				15. NUMBER OF PAGES 6
			· •	16. PRICE CODE
17. SECURITY CLASSIFICATION	18. SECURITY CLASSIFICATION	19. SECURITY CLASSI	FICATION	20. LIMITATION OF ABSTRACT
OF REPORT	OF THIS PAGE	OF ABSTRACT		
Unclassified	Unclassified	Unclassif	ied	Unlimited

	Unlimited					
Pre	andard Form 298 (Rev. 2-89) ascribed by ANSI Std. Z39-18 8-102					

OF REPORT Unclassified NSN 7540-01-280-5500

Table of Contents

ver	
SF 298	2
Table of Contents	3
Introduction	4
Body	4
Key Research Accomplishments	6
Reportable Outcomes	6
Conclusions	6
Reference	6

INTRODUCTION

The goal is to develop vaccination regimen to a tumor associated self-antigen, ErbB-2 and induce significant anti-tumor immunity in BALB NeuT mice which are tolerant to rat ErbB-2 (neu). The objectives are to

- (1) Measure vaccination efficacy after depletion of negative regulatory CD25⁺CD4⁺ cells.
- (2) Compare immune reactivity and tumor growth inhibition in ErbB-2 transgenic mice vaccinated with autologous or heterologous ErbB-2
- (3) Construct and test vaccination efficacy of ErbB-2 containing Pan DR Reactive Epitope (PADRE).


BODY

Immunization with DNA encoding tumor-associated antigen has demonstrated striking efficacy in mice ^{1,2}. Many tumor-associated antigens are, however, normal molecules over-expressed or inappropriately expressed. There may exist self-tolerance to such tumor associated antigens. To test the hypothesis that immunization with DNA vaccines encoding heterologous antigens can overcome tolerance and achieve anti-tumor effect, the cross-reactivity of human (Her-2) and rat ErbB-2 (neu) was first defined in BALB/c mice (Table 1). Mice were immunized twice by i.m. injection with 100 μ g each of pCMVE2TM and pEFBos GM-CSF. At two wks following the last immunization, mice were challenged by s.c. injection with 2 X 10⁵ D2F2 cells expressing human ErBB-2 (D2F2/E2) or rat neu (D2F2/neu). There was significant protection in all immunized mice, although complete protection was achieved only with autologous ErbB-2 vaccine. In mice immunized once and challenged with a TUBO cell line which was derived from a spontaneous tumor in NeuT transgenic female mice, only neuTM immunized mice were protected.


DNA vaccine, 2X	D2F2 tumor Expressing	Tu incidence	DNA vac, 1X. Challenge with	Tu incidence
Blank vector	Human ErbB-2	8/8		
pE2TM + pGM	Human ErbB-2	0/7		
pneuTM +p GM	Human ErbB-2	1/6		
Blank vector	Rat Neu	8/8	Tubo	3/3
pE2TM +p GM	Rat Neu	3/7	Tubo	3/3
pneuTM + pGM	Rat neu	0/7	Tubo	0/3

Table 1 Cross reactivity of Human and rat ErbB-2 in BALB/c mice

D2F2 cells are highly tumorigenic before ErbB-2 transfection and are independent of ErbB-2 for survival, whereas TUBO cells induced by transforming neu may depend on Neu for proliferation signals. Anti-ErbB-2 antibodies are not critical for D2F2/E2 or D2F2/neu rejection¹, but are primary effectors in TUBO rejection³. The inability to reject TUBO cells in mice immunized with pE2TM and pGM-CSF may indicate that anti-Her-2 antibody does not recognize rat neu. To test antibody cross-reactivity, sera was collected from mice which were immunized and had rejected D2F2 tumor expressing the corresponding antigen (Figure 1). Approximately 30 µg/ml of antibody was induced to the respective antigen, with little recognition of the heterologous Her-2 or Neu. This finding is both surprising and interesting and may indicate that ErbB-2 cross reactivity in BALB/c mice is mediated primarily by T cells.



Following this observation, it was expected that the spontaneous tumorigenesis in NeuT female mice would be suppressed by anti-Neu, but not anti-Her-2 antibody. BALB neuT females were immunized with DNA encoding GM-CSF combined with (A) blank vector (B) pE2TM or (C) pNeuTM (Figure 2). Total volume of the spontaneous tumors in each mouse was recorded. Significant delay in tumorigenesis was observed in NeuT mice immunized with pNeuTM, but not pE2TM.



Therefore, to overcome ErbB-2 tolerance, autologous antigen is more effective than heterologous antigen. To enhance the immunogenicity of ErbB-2, Pan DR Reactive Epitope (PADRE) sequence has been inserted into human ErbB-2 DNA and the vaccination efficacy is currently being tested.

KEY RESEARCH ACCOMPLISHMENTS

- 1. Define cross-reactivity of Her-2 and Neu in BALB/c mice
- 2. Demonstrate that vaccine induced anti-Her-2 or anti-neu antibody recognize only the autologous antigen.
- 3. Demonstrate that spontaneous tumorigenesis in BALB NeuT mice can be inhibited by immunization with rat neu, but not Her-2 DNA.

REPORTABLE OUTCOMES

Wei-Zen Wei, John Zielinski, Carmen Kelly, Katia Boggio*, Stefania Rovero* and Guido Forni*, "Autologous, but not heterologous, DNA vaccine inhibits spontaneous mammary tumorigenesis", DOD Era of Hope Conference, Orlando, Fl, 2002

CONCLUSIONS

Her-2 and rat neu are cross-reactive antigens in mice, but only autologous neu, not heterologous Her-2 induced protective immunity in NeuT transgenic mice and may indicate that vaccine induced antibodies recognize only autologous ErbB-2. To enhance the immunogenicity of autologous ErbB-2, an adjuvant sequence of Pan DR Reactive Epitope (PADRE) has been cloned into human ErbB-2 and the immunogenicity is being tested.

REFERENCE

- 1. Pilon, S., Piechocki, M. P., and Wei, W.-Z. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. The Journal of Immunology, *167*: 3201-3206, 2001.
- Wei, W. Z., Shi, W. P., Galy, A., Lichlyter, D., Hernandez, S., Groner, B., Heilbrun, L., and Jones, R. F. Protection Against Mammary Tumor Growth By Vaccination With Full-Length, Modified Human *ErbB-2* DNA. Int.J.Cancer, *81*: 748-754, 1999.
- Rovero, S., Amici, A., Di Carlo, E., Bei, R., Nanni, P., Quaglino, E., Porcedda, P., Boggio, K., Smorlesi, A., Lollini, P. L., Landuzzi, L., Colombo, M. P., Giovarelli, M., Musiani, P., and Forni, G. Inhibition of carcinogenesis by DNA vaccination. The Journal of Immunology, 165: 5133-5142, 2000.